Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

Fig. 5

DCZ0805 shows anti-tumor activity in a xenograft mouse model. a Photographs of tumor samples collected from MM-xenograft mice treated with DCZ0805 or the vehicle for 15 days. b The excised tumors were weighed on the 15th day of treatment. **P < 0.01 compared to the control group. c Tumor growth curve of MM-xenograft mice treated with DCZ0805 or vehicle for 15 days. Mean tumor volume (cm3) and standard deviation are shown (n = 4 mice/group, *P < 0.05 compared to the vehicle group. d The weight of mice was assessed daily for 15 days. Values are expressed as the means ± standard deviation. The difference between groups was not significant (P > 0.05). e H&E staining of tumor, liver and kidney sections removed from MM-xenograft mice treated with DCZ0805 or the vehicle; 400 × magnification. f Ki67 staining of the control and DCZ0805-treated xenograft tumor tissues

Back to article page